Topics
Glioblastoma | Treatment | Clinical trials | Temozolomide
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Temozolomide
Bhaskaran D, Savage J, Patel A,
Collinson F, Mant R, Boele F, Brazil L, Meade S, Buckle P, Lax S,
Billingham L, Short SC.
A
randomised phase II trial of temozolomide with or without
cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT):
protocol for a multi-centre, double-blind, placebo-controlled
trial.
BMC
Cancer. 2024 Jan
15;24(1):83. doi:
10.1186/s12885-023-11792-4. PMID:
38225549. Interventional
study protocol. ˍ
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Yamamoto
Y, Imai R, Kuranari Y, Tohmoto K, Hasegawa Y, Akasaki Y, Murayama
Y, Miyake K, Sasaki H.
An exploratory
prospective phase II study of preoperative neoadjuvant bevacizumab
and temozolomide for newly diagnosed glioblastoma.
J
Neurooncol. 2024 Jan 31. doi:
10.1007/s11060-023-04544-8. PMID:
38291182. Interventional
study. ˍ
Anvari K, Seilanian Toussi M, Saghafi M, Javadinia SA, Saghafi H,
Welsh JS.
Extended dosing (12 cycles)
vs conventional dosing (6 cycles) of adjuvant temozolomide in
adults with newly diagnosed high-grade gliomas: a randomized,
single-blind, two-arm, parallel-group controlled trial.
Front
Oncol. 2024 May 7;14:1357789. doi:
10.3389/fonc.2024.1357789. PMID:
38774410. Interventional
study. ˍ
*Sharifian A, Kazemian A, Farzin M, Amirkhani N, Farazmand B,
Naderi S, Khalilian A, Pourrashidi A, Amjad G, Kolahdouzan K,
Abyaneh R, Jablonska PA, Ghalehtaki R.
Postoperative
NEOadjuvant TEMozolomide followed by chemoradiotherapy versus
upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM)
trial: Interim results.
Neurooncol
Adv. 2024 Nov 14;6(1):vdae195. doi:
10.1093/noajnl/vdae195. PMID:
39664679. Interventional study. ˍ
Geurts M, Berchtold L, Koenig F, Nabors B, Reardon DA, Tonn JC,
Stupp R, Gorlia T, Weller M, Preusser M; EORTC Brain Tumor Group.
Temozolomide chemotherapy for patients
with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072
and CORE trials: Does time of administration matter?
Neurooncol
Pract. 2025 Jan 17;12(2):291-300. doi:
10.1093/nop/npaf006. PMID:
40110070. Observational study. ˍ
Chen B, Alder J.
A systematic review
of immunotherapies in combination with temozolomide as treatment
for glioblastoma.
Cancer
Treat Res Commun. 2025 Feb 24;43:100888. doi:
10.1016/j.ctarc.2025.100888. PMID:
40023003. Review. ˍ
Brown NF, McBain C, Brazil L,
Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C,
Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland
P.
Ipilimumab
with temozolomide vs. temozolomide alone after surgery and
chemoradiotherapy in recently diagnosed glioblastoma: a randomized
phase II clinical trial.
Neurooncol
Adv. 2025 May
26;7(1):vdaf032. doi:
10.1093/noajnl/vdaf032. PMID:
40800123. Interventional study. ˍ
Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman
M, Tran DD.
Efficacy and safety of
adjuvant TTFields plus pembrolizumab and temozolomide in newly
diagnosed glioblastoma: A phase 2 study.
Med.
2025 Jun 3:100708. doi:
10.1016/j.medj.2025.100708. PMID:
40466642. Interventional study. ˍ
Nakai K, Kumada H, Matsumoto Y, Baba K, Murakami M, Ishida T,
Saito T, Nakamura M, Numajiri H, Mizumoto M, Sugii N, Miki S,
Ishikawa E, Maruo K, Takemura M, Hashimoto K, Takahashi T, Hayashi
T, Sakurai H.
Boron neutron capture
therapy (BNCT) phase I clinical trial for newly diagnosed
glioblastoma by newly developed accelerator at University of
Tsukuba.
Appl
Radiat Isot. 2025 Sep 3;226:112152. doi:
10.1016/j.apradiso.2025.112152. PMID:
40945116.Interventional study protocol. ˍ